insights_auto
Prospettive: 63.6% di fonti rialziste·0.0% di fonti ribassiste
Vai all'analisichevron_right
NBIX:NASDAQ
Neurocrine Biosciences
136,54 USD
arrow_upward
+0,46%(+0,63) 1G
15 ott, 14:43:57 GMT-4 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per NBIX in corso…
Apertura
137,26 USD
Massimo
138,23 USD
Minimo
135,55 USD
Cap. mercato
13,88 Mld
Vol. medio
1,31 Mln
Volume
649,43K
Rapporto P/E
20,02
Max 52 sett.
186,12 USD
Min 52 sett.
122,14 USD
Utili per azione
6,82 USD
Beta
0,40
Azioni in circolazione
101,65 Mln
N. di dipendenti
2K
Apertura
137,26 USD
Massimo
138,23 USD
Minimo
135,55 USD
Cap. mercato
13,88 Mld
Vol. medio
1,31 Mln
Volume
649,43K
Rapporto P/E
20,02
Max 52 sett.
186,12 USD
Min 52 sett.
122,14 USD
Utili per azione
6,82 USD
Beta
0,40
Azioni in circolazione
101,65 Mln
N. di dipendenti
2K
Articoli giornalistici
Da fonti web e partner giornalistici
ad-hoc-news.de
·
51 minuti fa
RBC keeps USD 187.00 target for Neurocrine Biosciences stock
Stock Titan
·
1 ora fa
JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX)
Investing.com
·
1 giorno fa
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook
Profilo
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Informazioni su Neurocrine Biosciences
CEOKevin C. Gorman
Dipendenti2,5K
Data di fondazione1992
SedeSan Diego, California, Stati Uniti
Settore-
Sito webneurocrine.com